Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2025
Cyanotech Corporation (OTCQB: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2025, ended December 31, 2024.
Commenting on the third quarter fiscal year 2025 results, Cyanotech’s President and Chief Executive Officer, Matthew K. Custer, said:
“I am pleased by our continued progress in the third quarter, with a 10.6% increase in net sales, building on the momentum that we established in the first half of the fiscal year.”
“As we noted last quarter, our focus on inventory management and strategic restocking has allowed us to meet demand more effectively. The increase in our gross profit to 35.3% reflects the positive results of those efforts. While bulk sales are helping drive growth, addressing the slower growth of packaged sales remains a priority.”
“We’ve reduced our operating losses compared to last year, however, we remain focused on navigating these challenges and proceeding cautiously as we enter the next quarter.”
Third Quarter Fiscal 2025
Cyanotech reported net sales of $6,172,000 for the third quarter of fiscal 2025 compared to $5,582,000 for the third quarter of fiscal 2024, an increase of 10.6%. Gross profit was $2,179,000, with gross profit margin of 35.3%, compared to gross profit of $1,649,000, with gross profit margin of 29.5%. Operating loss for the third quarter of fiscal 2025 was $50,000 compared to operating loss of $848,000 in the same period of the prior year. Net loss for the current fiscal quarter was $224,000, or $0.03 per diluted share, compared to net loss of $1,020,000, or $0.16 per diluted share, for the same period of the prior year.
First Nine Months of Fiscal 2025
Cyanotech reported net sales of $17,915,000 for the first nine months of fiscal 2025 compared to $17,101,000 for the same period in fiscal 2024, an increase of 4.8%. Gross profit was $5,134,000, with gross profit margin of 28.7%, compared to gross profit of $5,270,000, with gross profit margin of 30.8%. Operating loss for the first nine months of fiscal 2025 was $2,066,000 compared to operating loss of $2,689,000 in the same period of the prior year. Net loss for the first nine months of fiscal 2025 was $2,576,000, or $0.37 per diluted share, compared to net loss of $3,186,000, or $0.50 per diluted share, for the same period of the prior year.
Trailing Twelve Months
For the trailing twelve months ended December 31, 2024, compared to the trailing twelve months ended December 31, 2023, net sales were $23,885,000 compared to $22,492,000, respectively. Gross profit was $5,810,000, with gross profit margin of 24.3%, compared to $6,656,000 and 29.6%. Net loss was $4,657,000, or $0.66 per diluted share, compared to net loss of $4,616,000, or $0.72 per diluted share.
Please review the Company’s Form 10-Q for the period ended December 31, 2024 for more detailed information.
---------------
— Cyanotech will host a virtual broadcast at 8:00 PM ET on Wednesday, February 12, 2025 to respond to questions about its operating results and other topics of interest. Interested parties are asked to submit questions to questions@cyanotech.com before 12 p.m. (noon) ET on Wednesday, February 12, 2025. The Company will respond only to relevant questions relating to the Company’s third quarter fiscal 2025 financial performance and will not be accepting any questions or comments during the broadcast.
To join the broadcast, please browse http://cyanotech.com/meet approximately five minutes prior to the start time.
---------------
About Cyanotech — Cyanotech Corporation, a world leader in microalgae technology for more than 30 years, produces BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica®. These all-natural, dietary ingredients and supplements leverage our experience and reputation for quality, building nutritional brands which promote health and well-being. The Company’s mission is to fulfill the promise of whole health through Hawaiian microalgae. Cyanotech’s BioAstin® offers superior antioxidant activity which supports skin, eye and joint health, as well as recovery from exercise*. Cyanotech's Spirulina products offer nutrition that supports cardiovascular health and immunity*. All Cyanotech products are produced from microalgae grown at our 96-acre facility in Kona, Hawaii using patented and proprietary technology and are Generally Recognized as Safe (“GRAS”) for use in food products. Cyanotech sells its products direct to consumers at retail locations in the United States and online at www.nutrex-hawaii.com and also distributes to dietary supplement, nutraceutical and cosmeceutical manufacturers and marketers. The Company is regulated by the Food and Drug Administration. Visit www.cyanotech.com for more information.
|
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. |
“Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995 Besides statements of present fact and historical fact, this press release may contain forward-looking statements. Forward-looking statements relate to the future and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by forward-looking statements. We caution against relying on forward-looking statements. Important factors that could change actual, future results include: changes in sales levels to our largest customers, weather patterns in Hawaii, production problems, risks associated with new products, foreign exchange fluctuations, and availability of financing, as well as national and global political, economic, business, competitive, market and regulatory conditions. Other factors are more fully detailed in the Company’s annual Form 10-K filings with the Securities and Exchange Commission.
Financial Tables Follow: The following tables do not contain footnotes or other information contained in the Company’s Form 10-Q for the third quarter fiscal 2025 ended December 31, 2024, which can be found on the Cyanotech website (www.cyanotech.com) under Investors>Investor Filings upon filing. As such, the following Financial Tables are provided only as a guide and other factors are more fully detailed in the Company’s annual Form 10-K filings with the Securities and Exchange Commission.
|
CYANOTECH CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share data) (Unaudited) |
||||||||
|
|
|
December 31,
|
|
March 31,
|
||||
|
ASSETS |
|
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
|
||
|
Cash |
|
$ |
359 |
|
|
$ |
707 |
|
|
Accounts receivable, net of allowance for credit losses of $29 and $11 as of December 31, 2024 and March 31, 2024, respectively |
|
|
1,908 |
|
|
|
2,102 |
|
|
Inventories |
|
|
7,751 |
|
|
|
7,313 |
|
|
Prepaid expenses and other current assets |
|
|
533 |
|
|
|
469 |
|
|
Total current assets |
|
|
10,551 |
|
|
|
10,591 |
|
|
|
|
|
|
|
|
|
||
|
Equipment and leasehold improvements, net |
|
|
9,256 |
|
|
|
10,109 |
|
|
Operating lease right-of-use assets, net |
|
|
4,032 |
|
|
|
4,284 |
|
|
Other assets |
|
|
117 |
|
|
|
128 |
|
|
Total assets |
|
$ |
23,956 |
|
|
$ |
25,112 |
|
|
|
|
|
|
|
|
|
||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
|
Current liabilities: |
|
|
|
|
|
|
||
|
Accounts payable |
|
$ |
2,151 |
|
|
$ |
1,439 |
|
|
Accrued expenses |
|
|
593 |
|
|
|
757 |
|
|
Customer deposits |
|
|
65 |
|
|
|
198 |
|
|
Operating lease obligations, current portion |
|
|
545 |
|
|
|
530 |
|
|
Short term debt - bank |
|
|
890 |
|
|
|
1,240 |
|
|
Line of credit – related party |
|
|
2,750 |
|
|
|
1,250 |
|
|
Current maturities of long-term debt |
|
|
2,955 |
|
|
|
3,140 |
|
|
Total current liabilities |
|
|
9,949 |
|
|
|
8,554 |
|
|
|
|
|
|
|
|
|
||
|
Long-term debt – related party |
|
|
1,000 |
|
|
|
1,000 |
|
|
Long-term operating lease obligations |
|
|
3,507 |
|
|
|
3,744 |
|
|
Total liabilities |
|
|
14,456 |
|
|
|
13,298 |
|
|
|
|
|
|
|
|
|
||
|
Commitments and contingencies |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
Stockholders’ equity: |
|
|
|
|
|
|
||
|
Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding |
|
|
— |
|
|
|
— |
|
|
Common stock of $0.02 par value, authorized 50,000,000 shares; issued and outstanding 7,155,858 shares at December 31, 2024 and 6,947,246 shares at March 31, 2024 |
|
|
143 |
|
|
|
139 |
|
|
Additional paid-in capital |
|
|
34,834 |
|
|
|
34,576 |
|
|
Accumulated deficit |
|
|
(25,477 |
) |
|
|
(22,901 |
) |
|
Total stockholders’ equity |
|
|
9,500 |
|
|
|
11,814 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
23,956 |
|
|
$ |
25,112 |
|
|
CYANOTECH CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands) (Unaudited) |
||||||||||||||||
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net sales |
|
$ |
6,172 |
|
|
$ |
5,582 |
|
|
$ |
17,915 |
|
|
$ |
17,101 |
|
|
Cost of sales |
|
|
3,993 |
|
|
|
3,933 |
|
|
|
12,781 |
|
|
|
11,831 |
|
|
Gross profit |
|
|
2,179 |
|
|
|
1,649 |
|
|
|
5,134 |
|
|
|
5,270 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
General and administrative |
|
|
1,012 |
|
|
|
947 |
|
|
|
3,524 |
|
|
|
3,381 |
|
|
Sales and marketing |
|
|
1,090 |
|
|
|
1,387 |
|
|
|
3,328 |
|
|
|
4,048 |
|
|
Research and development |
|
|
127 |
|
|
|
163 |
|
|
|
348 |
|
|
|
530 |
|
|
Total operating expenses |
|
|
2,229 |
|
|
|
2,497 |
|
|
|
7,200 |
|
|
|
7,959 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Loss from operations |
|
|
(50 |
) |
|
|
(848 |
) |
|
|
(2,066 |
) |
|
|
(2,689 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Interest expense, net |
|
|
(174 |
) |
|
|
(172 |
) |
|
|
(510 |
) |
|
|
(495 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Loss before income taxes |
|
|
(224 |
) |
|
|
(1,020 |
) |
|
|
(2,576 |
) |
|
|
(3,184 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Income tax expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net loss |
|
$ |
(224 |
) |
|
$ |
(1,020 |
) |
|
$ |
(2,576 |
) |
|
$ |
(3,186 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Basic and diluted |
|
$ |
(0.03 |
) |
|
$ |
(0.16 |
) |
|
$ |
(0.37 |
) |
|
$ |
(0.50 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Shares used in calculation of net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Basic and diluted |
|
|
7,156 |
|
|
|
6,554 |
|
|
|
7,036 |
|
|
|
6,404 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211948393/en/
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
